A Triple-Mismatch Differentiating assay exploiting activation and trans cleavage of CRISPR-Cas12a for mutation detection with ultra specificity and sensitivity
Authors:
- 30 September 2024
- journal article
- research article
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 267, 116826
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Next batter up! Targeting cancers with KRAS-G12D mutationsTrends in Cancer, 2023
- Cas12a/blocker DNA-based multiplex nucleic acid detection system for diagnosis of high-risk human papillomavirus infectionBiosensors and Bioelectronics, 2023
- Next-generation sequencing technologies: An overviewHuman Immunology, 2021
- Pancreatic CancerJAMA, 2021
- Early screening and diagnosis strategies of pancreatic cancer: a comprehensive reviewCancer Communications, 2021
- Pancreatic cancerThe Lancet, 2020
- Early detection of pancreatic cancerThe Lancet Gastroenterology & Hepatology, 2020
- Pancreatic cancerThe Lancet, 2016
- Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas SystemCell, 2015
- Real-time PCR detection chemistryClinica Chimica Acta, 2015